Article Listing - Cephalon swings to profit in 2nd-qtr 2006
US Supreme Court issues mixed ruling on DNA patents
14 June 2013
The US Supreme Court yesterday (June 13) delivered its unanimous decision regarding the Association for Molecular Pathology versus Myriad Genetics case on patent claims on isolated DNA molecules, stating that companies cannot patent specific DNA, but that synthetically produced genetic material can be patented.
Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid
14 June 2013
Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the company revealed that the first part of its phase II clinical study combining the HIV vaccine, Vacc-4x, with Celgene's immunomodulator, Revlimid (lenalidomide), has been successfully completed.
NICE says "yes" to Alimera's Iluvien for treatment of diabetic macular edema
14 June 2013
In draft guidance published today (June 14) by UK drugs watch dog the National Institute for Health and Care Excellence (NICE) it is recommending US ophthalmic biopharma specialist Alimira Sciences (Nasdaq: ALIM) Iluvien (fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies, reversing a prior draft guidance last summer (The Pharma Letter August 8, 2012).
Genetics and genomics industry in the USA has a trillion dollar impact, new Battelle study shows
14 June 2013
A new Battelle study released this week by United for Medical Research illustrates the genetics and genomics industry's impact on the US economy has reached nearly a trillion dollars. The study is based on new data collected over the previous two years, and represents an update to the highly-cited Battelle 2011 report tracking the growth of the industry and its links to the federally funded Human Genome Project (HGP).
EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib
13 June 2013
Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech firm Celgene (Nasdaq: CELG) presented positive data from a third Phase III randomized controlled study, dubbed PALACE 3, of apremilast in psoriatic arthritis.
Turkey's NSCLC drug market forecast to expand at 7% a year through 2017
13 June 2013
From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual rate of 7%, reaching a value of $73 million in 2017, according to a new report from health care advisory firm Decision Resources.
Sunesis Pharma's VALOR trial of vosaroxin should continue with no change, says DSMB
13 June 2013
Sunesis Pharmaceuticals (Nasdaq: SNSS) says that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed its latest periodic safety review and recommended that the trial continue as planned without changes to study conduct.
Sagent Pharma expands voluntary withdrawal of vecuronium inj vials
13 June 2013
US drugmaker Sagent Pharmaceuticals (Nasdaq: SGNT) said today (June 13) that it is expanding its voluntary nationwide recall of vecuronium bromide for injection 10mg (NDC number 25021-657-10) manufactured by Turkey-based Mustafa Nevzat Ilac Sanayii (MN Pharmaceuticals) and distributed by Sagent. This recall is being conducted with the knowledge of the US Food and Drug Administration.
Increased focus on generics and biosimilars only way to make European health care sustainable, says EGA
13 June 2013
Addressing delegates at the 19th European Generic medicines Association (EGA) Annual Conference in Athens, Greece, its president Gudbjorg Edda Eggertsdottir stressed that generic and biosimilar medicines companies ensuring high-quality manufacturing jobs and know-how should remain in Europe; benefiting society and patients and increasing the competitiveness and innovative capacity of this strategic industry.
Amgen's trebananib meets primary end-point in Ph III study of recurrent ovarian cancer
13 June 2013
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced that the Phase III TRINOVA-1 trial evaluating trebananib (AMG 386) plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS).
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
